COMMUNIQUÉS West-GlobeNewswire

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
11/08/2025
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease 1 Ianalumab [...]
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
11/08/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 11, 2025 Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204 * million convertible bonds [...]
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025
11/08/2025
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), [...]
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
11/08/2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a [...]
AVITA Medical to Host Investor Webinar Briefing
11/08/2025
VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective [...]
RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
10/08/2025
Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive [...]
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
10/08/2025
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 [...]
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
09/08/2025
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum [...]
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
09/08/2025
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE [...]
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
08/08/2025
Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound Healing TORONTO and HAIFA, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90 [...]
Heartland Physio Unveils The R.E.A.L. Recovery Experience for Singapore’s Active Professionals
08/08/2025
A personalised, root-cause approach that challenges one-size-fits-all physiotherapy. Singapore, Singapore, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Heartland Physio is proud to unveil its signature R.E.A.L. Recovery™ [...]
Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025
08/08/2025
Company to host an investor conference call and webcast at 4:30 pm ET NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi , Inc. (NASDAQ: HYPD), the first U.S. public company to build a strategic treasury around [...]
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
08/08/2025
F DA provides pivotal agreement on EB613 Phase 3 design, confirming B one M ineral D ensity (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment Significant [...]
Amwell makes grant to new employees under inducement plan
08/08/2025
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading technology-enabled care platform provider, announces that on August 8, Amwell made grants of RSUs covering an aggregate of 76,198 shares of its [...]
Femasys Announces Second Quarter Financial Results for 2025
08/08/2025
-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/08/2025
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards [...]
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
08/08/2025
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the [...]
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
08/08/2025
Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision [...]
Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil
08/08/2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil Lancement Officiel de la Commercialisation aux [...]

Pages